Article Text

Download PDFPDF
Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus
  1. D Albert1,
  2. J Dunham2,
  3. S Khan2,
  4. J Stansberry2,
  5. S Kolasinski2,
  6. D Tsai2,
  7. S Pullman-Mooar2,
  8. F Barnack2,
  9. C Striebich3,
  10. R J Looney4,
  11. E T Luning Prak2,
  12. R Kimberly5,
  13. Y Zhang2,
  14. R Eisenberg2
  1. 1
    Dartmouth Medical School, Hanover, New Hampshire, USA
  2. 2
    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
  3. 3
    University of Colorado Health Science Center, Aurora, Colorado, USA
  4. 4
    University of Rochester, Rochester, New York, USA
  5. 5
    University of Alabama at Birmingham, Birmingham, Alabama, USA
  1. Robert Eisenberg, University of Pennsylvania, Department of Rheumatology, 756 BRB II/III, 421 Curie Blvd, Philadelphia, Pennsylvania 19104–6160, USA; raemd{at}


Objective: To study the effects in systemic lupus erythaematosus (SLE) of B cell directed therapy with rituximab, a chimeric monoclonal antibody directed at CD20+ B cells, without concomitant immunosuppressive therapy in mild to moderate SLE.

Methods: Patients (n = 24) with active SLE and failure of ⩾1 immunosuppressive were recruited from three university centres into this phase I/II prospective open-label study. Patients were followed for 1 year to assess safety, efficacy and biological effects.

Results: In total, 18 of the patients scheduled to receive the full lymphoma dose of rituximab were evaluable for B cell levels in peripheral blood. Of these, 17 had effective CD19+ B cell depletion (<5 cells/μl). However, six of the depleted patients showed B cell return before 24 weeks. A total of 70% of patients improved by week 55, as defined by an SLE Disease Activity Index (SLEDAI) score improvement of ⩾2 units from baseline. The degree of CD19+ B cell depletion was correlated with SLEDAI improvement at week 15 (r = 0.84). In general, rituximab infusions were well tolerated. Approximately a third of the patients developed human anti-chimeric antibody (HACA) titres, which correlated with poor B cell depletion. Most patients (9 of 14) did not respond to immunisations with Pneumovax and tetanus toxoid.

Conclusions: Rituximab is a promising new therapy for SLE. The variability of responses in patients with SLE may be related to HACA formation. The failure to respond to immunisations is surprising, in view of the apparently low risk of infections. Better biological markers are necessary to follow these patients during treatment.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: This work was in part supported by the US distributors of rituximab, Genentech, and RE, DA, ETLP and RJL have consulted with Genentech on B cell depletion in systemic lupus erythaematosus.

  • Funding: Support for this study was provided by the National Institutes for Health (National Institute of Allergy and Infectious Diseases) through the Autoimmune Centers of Excellence (U19AI-46358), by grants from the Alliance for Lupus Research, the Lupus Clinical Trials Consortium and from Genentech, San Francisco, California, USA. Patients enrolled in Colorado were also supported by their General Clinical Research Center through a grant (MO1 RR00051).

  • Ethics approval: All patients gave written informed consent before starting the study. The protocol and consent form were approved by the institutional review board at each university.